GSK 6-K
GSK plc (GSK)
6-K
2024-10-17
For: 2024-10-17
View Original
Added on
April 10, 2026
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of October 2024
Commission File Number 001-15170
GSK plc
(Translation of registrant's name into English)
79 New Oxford Street, London, WC1A 1DG
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
GSK plc (the 'Company')
Transaction notification
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||
|---|---|---|---|
| a) | Name | Emma Walmsley | |
| b) | Position/status | Chief Executive Officer | |
| c) | Initial<br>notification/ amendment | Initial notification | |
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||
| a) | Name | GSK plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br> <br><br><br>ISIN: GB00BN7SWP63 | |
| b) | Nature<br>of the transaction | Increase in notional interest in Ordinary Shares following the<br>re-investment of dividends paid to shareholders on 10 October 2024<br>on Ordinary Shares held in the Company's Deferred Annual Bonus<br>Plan | |
| c) | Price(s)<br>and volume(s) | Volume(s) | |
| 797 | |||
| 1,324 | |||
| 1,497 | |||
| d) | Aggregated<br>information | ||
| Aggregated<br>volume<br><br><br><br><br><br>Price | 3,618<br><br> <br><br><br>15.0500 | ||
| e) | Date<br>of the transaction | 2024-10-15 | |
| f) | Place<br>of the transaction | London Stock Exchange (XLON) |
All values are in British Pounds.
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
|---|---|---|---|---|
| a) | Name | Dr Hal Barron | ||
| b) | Position/status | Non-Executive Director | ||
| c) | Initial<br>notification/ amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | American Depositary Shares ('ADSs')<br><br><br><br><br><br>ISIN: US37733W2044 | ||
| b) | Nature<br>of the transaction | Increase in notional interest in ADSs following the re-investment<br>of dividends paid to shareholders on 10 October 2024 on ADSs held<br>in the Company's Deferred Annual Bonus Plan | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| $39.2100 | 431 | |||
| d) | Aggregated<br>information | N/A (single transaction) | ||
| Aggregated<br>volume<br><br><br><br><br><br>Price | ||||
| e) | Date<br>of the transaction | 2024-10-15 | ||
| f) | Place<br>of the transaction | New York Stock Exchange (XNYS) | ||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
| --- | --- | --- | --- | --- |
| a) | Name | Julie Brown | ||
| b) | Position/status | Chief Financial Officer | ||
| c) | Initial<br>notification/ amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br><br><br><br>ISIN: GB00BN7SWP63 | ||
| b) | Nature<br>of the transaction | Increase in notional interest in Ordinary Shares following the<br>re-investment of dividends paid to shareholders on 10 October 2024<br>on Ordinary Shares held in the Company's Deferred Annual Bonus<br>Plan | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| £15.0500 | 571 | |||
| d) | Aggregated<br>information | N/A (single transaction) | ||
| Aggregated<br>volume<br><br><br><br><br><br>Price | ||||
| e) | Date<br>of the transaction | 2024-10-15 | ||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) | ||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
| --- | --- | --- | --- | |
| a) | Name | Diana Conrad | ||
| b) | Position/status | Chief People Officer | ||
| c) | Initial<br>notification/ amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br> <br><br><br>ISIN: GB00BN7SWP63 | ||
| b) | Nature<br>of the transaction | Increase in notional interest in Ordinary Shares following the<br>re-investment of dividends paid to shareholders on 10 October 2024<br>on Ordinary Shares held in the Company's Deferred Annual Bonus<br>Plan | ||
| c) | Price(s)<br>and volume(s) | Volume(s) | ||
| 125 | ||||
| 241 | ||||
| 377 | ||||
| d) | Aggregated<br>information | |||
| Aggregated<br>volume<br><br><br><br><br><br>Price | 743<br><br> <br><br><br>15.0500 | |||
| e) | Date<br>of the transaction | 2024-10-15 | ||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) |
All values are in British Pounds.
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||
|---|---|---|---|
| a) | Name | James Ford | |
| b) | Position/status | SVP and Group General Counsel, Legal and Compliance | |
| c) | Initial<br>notification/ amendment | Initial notification | |
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||
| a) | Name | GSK plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br> <br><br><br>ISIN: GB00BN7SWP63 | |
| b) | Nature<br>of the transaction | Increase in notional interest in Ordinary Shares following the<br>re-investment of dividends paid to shareholders on 10 October 2024<br>on Ordinary Shares held in the Company's Deferred Annual Bonus<br>Plan | |
| c) | Price(s)<br>and volume(s) | Volume(s) | |
| 154 | |||
| 234 | |||
| 382 | |||
| d) | Aggregated<br>information | ||
| Aggregated<br>volume<br><br><br><br><br><br>Price | 770<br><br> <br><br><br>15.0500 | ||
| e) | Date<br>of the transaction | 2024-10-15 | |
| f) | Place<br>of the transaction | London Stock Exchange (XLON) |
All values are in British Pounds.
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||
|---|---|---|---|
| a) | Name | Sally Jackson | |
| b) | Position/status | SVP, Global Communications and CEO Office | |
| c) | Initial<br>notification/ amendment | Initial notification | |
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||
| a) | Name | GSK plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br><br><br><br>ISIN: GB00BN7SWP63 | |
| b) | Nature<br>of the transaction | Increase in notional interest in Ordinary Shares following the<br>re-investment of dividends paid to shareholders on 10 October 2024<br>on Ordinary Shares held in the Company's Deferred Annual Bonus<br>Plan | |
| c) | Price(s)<br>and volume(s) | Volume(s) | |
| 71 | |||
| 145 | |||
| 236 | |||
| d) | Aggregated<br>information | ||
| Aggregated<br>volume<br><br><br><br><br><br>Price | 452<br><br> <br><br><br>15.0500 | ||
| e) | Date<br>of the transaction | 2024-10-15 | |
| f) | Place<br>of the transaction | London Stock Exchange (XLON) |
All values are in British Pounds.
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||
|---|---|---|---|
| a) | Name | Luke Miels | |
| b) | Position/status | Chief Commercial Officer | |
| c) | Initial<br>notification/ amendment | Initial notification | |
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||
| a) | Name | GSK plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br><br><br><br>ISIN: GB00BN7SWP63 | |
| b) | Nature<br>of the transaction | Increase in notional interest in Ordinary Shares following the<br>re-investment of dividends paid to shareholders on 10 October 2024<br>on Ordinary Shares held in the Company's Deferred Annual Bonus<br>Plan | |
| c) | Price(s)<br>and volume(s) | Volume(s) | |
| 262 | |||
| 564 | |||
| 711 | |||
| d) | Aggregated<br>information | ||
| Aggregated<br>volume<br><br><br><br><br><br>Price | 1,537<br><br> <br><br><br>15.0500 | ||
| e) | Date<br>of the transaction | 2024-10-15 | |
| f) | Place<br>of the transaction | London Stock Exchange (XLON) |
All values are in British Pounds.
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||
|---|---|---|---|
| a) | Name | Shobie Ramakrishnan | |
| b) | Position/status | Chief Digital and Technology Officer | |
| c) | Initial<br>notification/ amendment | Initial notification | |
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||
| a) | Name | GSK plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||
| a) | Description<br>of the financial instrument | American Depositary Shares ('ADSs')<br><br><br> <br><br><br>ISIN: US37733W2044 | |
| b) | Nature<br>of the transaction | Increase in notional interest in ADSs following the re-investment<br>of dividends paid to shareholders on 10 October 2024 on ADSs held<br>in the Company's Deferred Annual Bonus Plan | |
| c) | Price(s)<br>and volume(s) | Volume(s) | |
| 26 | |||
| 113 | |||
| 176 | |||
| d) | Aggregated<br>information | ||
| Aggregated<br>volume<br><br><br><br><br><br>Price | 315<br><br> <br><br><br>39.2100 | ||
| e) | Date<br>of the transaction | 2024-10-15 | |
| f) | Place<br>of the transaction | New York Stock Exchange (XNYS) |
All values are in US Dollars.
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||
|---|---|---|---|
| a) | Name | David Redfern | |
| b) | Position/status | President, Corporate Development | |
| c) | Initial<br>notification/ amendment | Initial notification | |
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||
| a) | Name | GSK plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br><br><br><br>ISIN: GB00BN7SWP63 | |
| b) | Nature<br>of the transaction | Increase in notional interest in Ordinary Shares following the<br>re-investment of dividends paid to shareholders on 10 October 2024<br>on Ordinary Shares held in the Company's Deferred Annual Bonus<br>Plan | |
| c) | Price(s)<br>and volume(s) | Volume(s) | |
| 173 | |||
| 326 | |||
| 452 | |||
| d) | Aggregated<br>information | ||
| Aggregated<br>volume<br><br><br><br><br><br>Price | 951<br><br> <br><br><br>15.0500 | ||
| e) | Date<br>of the transaction | 2024-10-15 | |
| f) | Place<br>of the transaction | London Stock Exchange (XLON) |
All values are in British Pounds.
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||
|---|---|---|---|
| a) | Name | Regis Simard | |
| b) | Position/status | President, Global Supply Chain | |
| c) | Initial<br>notification/ amendment | Initial notification | |
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||
| a) | Name | GSK plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br><br><br><br>ISIN: GB00BN7SWP63 | |
| b) | Nature<br>of the transaction | Increase in notional interest in Ordinary Shares following the<br>re-investment of dividends paid to shareholders on 10 October 2024<br>on Ordinary Shares held in the Company's Deferred Annual Bonus<br>Plan | |
| c) | Price(s)<br>and volume(s) | Volume(s) | |
| 157 | |||
| 262 | |||
| 545 | |||
| d) | Aggregated<br>information | ||
| Aggregated<br>volume<br><br><br><br><br><br>Price | 964<br><br> <br><br><br>15.0500 | ||
| e) | Date<br>of the transaction | 2024-10-15 | |
| f) | Place<br>of the transaction | London Stock Exchange (XLON) |
All values are in British Pounds.
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||
|---|---|---|---|
| a) | Name | Philip Thomson | |
| b) | Position/status | President, Global Affairs | |
| c) | Initial<br>notification/ amendment | Initial notification | |
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||
| a) | Name | GSK plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br><br><br><br>ISIN: GB00BN7SWP63 | |
| b) | Nature<br>of the transaction | Increase in notional interest in Ordinary Shares following the<br>re-investment of dividends paid to shareholders on 10 October 2024<br>on Ordinary Shares held in the Company's Deferred Annual Bonus<br>Plan | |
| c) | Price(s)<br>and volume(s) | Volume(s) | |
| 109 | |||
| 171 | |||
| 304 | |||
| d) | Aggregated<br>information | ||
| Aggregated<br>volume<br><br><br><br><br><br>Price | 584<br><br> <br><br><br>15.0500 | ||
| e) | Date<br>of the transaction | 2024-10-15 | |
| f) | Place<br>of the transaction | London Stock Exchange (XLON) |
All values are in British Pounds.
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||
|---|---|---|---|
| a) | Name | Deborah Waterhouse | |
| b) | Position/status | CEO, ViiV Healthcare and President, Global Health, GSK | |
| c) | Initial<br>notification/ amendment | Initial notification | |
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||
| a) | Name | GSK plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br><br><br><br>ISIN: GB00BN7SWP63 | |
| b) | Nature<br>of the transaction | Increase in notional interest in Ordinary Shares following the<br>re-investment of dividends paid to shareholders on 10 October 2024<br>on Ordinary Shares held in the Company's Deferred Annual Bonus<br>Plan | |
| c) | Price(s)<br>and volume(s) | Volume(s) | |
| 115 | |||
| 417 | |||
| 471 | |||
| d) | Aggregated<br>information | ||
| Aggregated<br>volume<br><br><br><br><br><br>Price | 1,003<br><br> <br><br><br>15.0500 | ||
| e) | Date<br>of the transaction | 2024-10-15 | |
| f) | Place<br>of the transaction | London Stock Exchange (XLON) |
All values are in British Pounds.
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||
|---|---|---|---|
| a) | Name | Tony Wood | |
| b) | Position/status | Chief Scientific Officer | |
| c) | Initial<br>notification/ amendment | Initial notification | |
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||
| a) | Name | GSK plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br><br><br><br>ISIN: GB00BN7SWP63 | |
| b) | Nature<br>of the transaction | Increase in notional interest in Ordinary Shares following the<br>re-investment of dividends paid to shareholders on 10 October 2024<br>on Ordinary Shares held in the Company's Deferred Annual Bonus<br>Plan | |
| c) | Price(s)<br>and volume(s) | Volume(s) | |
| 198 | |||
| 580 | |||
| d) | Aggregated<br>information | ||
| Aggregated<br>volume<br><br><br><br><br><br>Price | 778<br><br> <br><br><br>15.0500 | ||
| e) | Date<br>of the transaction | 2024-10-15 | |
| f) | Place<br>of the transaction | London Stock Exchange (XLON) |
All values are in British Pounds.
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
|---|---|---|---|---|
| a) | Name | Emma Walmsley | ||
| b) | Position/status | Chief Executive Officer | ||
| c) | Initial<br>notification/ amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br><br><br><br>ISIN: GB00BN7SWP63 | ||
| b) | Nature of<br>the transaction | Acquisition of Ordinary Shares following the re-investment of<br>dividends paid to shareholders on 10 October 2024 on Ordinary<br>Shares held in the Company's Performance Share Plan subject to a<br>2-year holding period | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| £15.0500 | 7103.562 | |||
| d) | Aggregated information<br><br><br><br><br><br>Aggregated volume<br><br><br><br><br><br>Price | N/A (single transaction) | ||
| e) | Date<br>of the transaction | 2024-10-15 | ||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) | ||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
| --- | --- | --- | --- | --- |
| a) | Name | Emma Walmsley | ||
| b) | Position/status | Chief Executive Officer | ||
| c) | Initial<br>notification/ amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br><br><br><br>ISIN: GB00BN7SWP63 | ||
| b) | Nature<br>of the transaction | Acquisition of Ordinary Shares following the re-investment of<br>dividends paid to shareholders on 10 October 2024 | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| £14.8747 | 1,907.049 | |||
| d) | Aggregated<br>information | N/A (single transaction) | ||
| Aggregated<br>volume<br><br><br><br><br><br>Price | ||||
| e) | Date<br>of the transaction | 2024-10-15 | ||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) | ||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
| --- | --- | --- | --- | --- |
| a) | Name | Diana Conrad | ||
| b) | Position/status | Chief People Officer | ||
| c) | Initial<br>notification/ amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br><br><br><br>ISIN: GB00BN7SWP63 | ||
| b) | Nature<br>of the transaction | Acquisition of Ordinary Shares following the re-investment of<br>dividends paid to shareholders on 10 October 2024 | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| £14.8747 | 750.705 | |||
| d) | Aggregated<br>information | N/A (single transaction) | ||
| Aggregated<br>volume<br><br><br><br><br><br>Price | ||||
| e) | Date<br>of the transaction | 2024-10-15 | ||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) | ||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
| --- | --- | --- | --- | --- |
| a) | Name | James Ford | ||
| b) | Position/status | SVP and Group General Counsel, Legal and Compliance | ||
| c) | Initial<br>notification/ amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br><br><br><br>ISIN: GB00BN7SWP63 | ||
| b) | Nature<br>of the transaction | Acquisition of Ordinary Shares following the re-investment of<br>dividends paid to shareholders on 10 October 2024 | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| £14.8747 | 1,314.382 | |||
| d) | Aggregated<br>information | N/A (single transaction) | ||
| Aggregated<br>volume<br><br><br><br><br><br>Price | ||||
| e) | Date<br>of the transaction | 2024-10-15 | ||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) | ||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
| --- | --- | --- | --- | --- |
| a) | Name | Sally Jackson | ||
| b) | Position/status | SVP, Global Communications and CEO Office | ||
| c) | Initial<br>notification/ amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br><br><br><br>ISIN: GB00BN7SWP63 | ||
| b) | Nature<br>of the transaction | Acquisition of Ordinary Shares following the re-investment of<br>dividends paid to shareholders on 10 October 2024 | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| £14.8747 | 460.952 | |||
| d) | Aggregated<br>information | N/A (single transaction) | ||
| Aggregated<br>volume<br><br><br><br><br><br>Price | ||||
| e) | Date<br>of the transaction | 2024-10-15 | ||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) | ||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
| --- | --- | --- | --- | --- |
| a) | Name | Dylan Jackson | ||
| b) | Position/status | PCA of Sally Jackson (SVP, Global Communications and CEO<br>Office) | ||
| c) | Initial<br>notification/ amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br><br><br><br>ISIN: GB00BN7SWP63 | ||
| b) | Nature<br>of the transaction | Acquisition of Ordinary Shares following the re-investment of<br>dividends paid to shareholders on 10 October 2024 | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| £14.8747 | 138.675 | |||
| d) | Aggregated<br>information | N/A (single transaction) | ||
| Aggregated<br>volume<br><br><br><br><br><br>Price | ||||
| e) | Date<br>of the transaction | 2024-10-15 | ||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) | ||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
| --- | --- | --- | --- | --- |
| a) | Name | Luke Miels | ||
| b) | Position/status | Chief Commercial Officer | ||
| c) | Initial<br>notification/ amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br><br><br><br>ISIN: GB00BN7SWP63 | ||
| b) | Nature<br>of the transaction | Acquisition of Ordinary Shares following the re-investment of<br>dividends paid to shareholders on 10 October 2024 | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| £14.8747 | 8,065.319 | |||
| d) | Aggregated<br>information | N/A (single transaction) | ||
| Aggregated<br>volume<br><br><br><br><br><br>Price | ||||
| e) | Date<br>of the transaction | 2024-10-15 | ||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) | ||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
| --- | --- | --- | --- | --- |
| a) | Name | David Redfern | ||
| b) | Position/status | President Corporate Development | ||
| c) | Initial<br>notification/ amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br><br><br><br>ISIN: GB00BN7SWP63 | ||
| b) | Nature<br>of the transaction | Acquisition of Ordinary Shares following the re-investment of<br>dividends paid to shareholders on 10 October 2024 | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| £14.8747 | 5,312.283 | |||
| d) | Aggregated<br>information | N/A (single transaction) | ||
| Aggregated<br>volume<br><br><br><br><br><br>Price | ||||
| e) | Date<br>of the transaction | 2024-10-15 | ||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) | ||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
| --- | --- | --- | --- | --- |
| a) | Name | Regis Simard | ||
| b) | Position/status | President, Global Supply Chain | ||
| c) | Initial<br>notification/ amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br><br><br><br>ISIN: GB00BN7SWP63 | ||
| b) | Nature<br>of the transaction | Acquisition of Ordinary Shares following the re-investment of<br>dividends paid to shareholders on 10 October 2024 | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| £14.8747 | 1,795.389 | |||
| d) | Aggregated<br>information | N/A (single transaction) | ||
| Aggregated<br>volume<br><br><br><br><br><br>Price | ||||
| e) | Date<br>of the transaction | 2024-10-15 | ||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) | ||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
| --- | --- | --- | --- | --- |
| a) | Name | Philip Thomson | ||
| b) | Position/status | President, Global Affairs | ||
| c) | Initial<br>notification/ amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br><br><br><br>ISIN: GB00BN7SWP63 | ||
| b) | Nature<br>of the transaction | Acquisition of Ordinary Shares following the re-investment of<br>dividends paid to shareholders on 10 October 2024 | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| £14.8747 | 1,691.777 | |||
| d) | Aggregated<br>information | N/A (single transaction) | ||
| Aggregated<br>volume<br><br><br><br><br><br>Price | ||||
| e) | Date<br>of the transaction | 2024-10-15 | ||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) | ||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
| --- | --- | --- | --- | --- |
| a) | Name | Kate Thomson | ||
| b) | Position/status | PCA of Philip Thomson (President, Global Affairs) | ||
| c) | Initial<br>notification/ amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br><br><br><br>ISIN: GB00BN7SWP63 | ||
| b) | Nature<br>of the transaction | Acquisition of Ordinary Shares following the re-investment of<br>dividends paid to shareholders on 10 October 2024 | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| £14.8747 | 108.184 | |||
| d) | Aggregated<br>information | N/A (single transaction) | ||
| Aggregated<br>volume<br><br><br><br><br><br>Price | ||||
| e) | Date<br>of the transaction | 2024-10-15 | ||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) | ||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
| --- | --- | --- | --- | --- |
| a) | Name | Deborah Waterhouse | ||
| b) | Position/status | CEO, ViiV Healthcare and President, Global Health, GSK | ||
| c) | Initial<br>notification/ amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br><br><br><br>ISIN: GB00BN7SWP63 | ||
| b) | Nature<br>of the transaction | Acquisition of Ordinary Shares following the re-investment of<br>dividends paid to shareholders on 10 October 2024 | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| £14.8747 | 505.542 | |||
| d) | Aggregated<br>information | N/A (single transaction) | ||
| Aggregated<br>volume<br><br><br><br><br><br>Price | ||||
| e) | Date<br>of the transaction | 2024-10-15 | ||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) | ||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
| --- | --- | --- | --- | --- |
| a) | Name | Tony Wood | ||
| b) | Position/status | Chief Scientific Officer | ||
| c) | Initial<br>notification/ amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br><br><br><br>ISIN: GB00BN7SWP63 | ||
| b) | Nature<br>of the transaction | Acquisition of Ordinary Shares following the re-investment of<br>dividends paid to shareholders on 10 October 2024 | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| £14.8747 | 617.500 | |||
| d) | Aggregated<br>information | N/A (single transaction) | ||
| Aggregated<br>volume<br><br><br><br><br><br>Price | ||||
| e) | Date<br>of the transaction | 2024-10-15 | ||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) | ||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
| --- | --- | --- | --- | --- |
| a) | Name | Dr Hal Barron | ||
| b) | Position/status | Non-Executive Director | ||
| c) | Initial<br>notification/ amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | American Depositary Shares ('ADSs')<br><br><br><br><br><br>ISIN: US37733W2044 | ||
| b) | Nature<br>of the transaction | Acquisition of ADSs following the re-investment of dividends paid<br>to shareholders on 10 October 2024 | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| $39.2062 | 2,916.813 | |||
| d) | Aggregated<br>information | N/A (single transaction) | ||
| Aggregated<br>volume<br><br><br><br><br><br>Price | ||||
| e) | Date<br>of the transaction | 2024-10-15 | ||
| f) | Place<br>of the transaction | New York Stock Exchange (XNYS) | ||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
| --- | --- | --- | --- | --- |
| a) | Name | James Ford | ||
| b) | Position/status | SVP and Group General Counsel, Legal and Compliance | ||
| c) | Initial<br>notification/ amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | American Depositary Shares ('ADSs')<br><br><br><br><br><br>ISIN: US37733W2044 | ||
| b) | Nature<br>of the transaction | Acquisition of ADSs following the re-investment of dividends paid<br>to shareholders on 10 October 2024 | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| $39.2062 | 314.760 | |||
| d) | Aggregated<br>information | N/A (single transaction) | ||
| Aggregated<br>volume<br><br><br><br><br><br>Price | ||||
| e) | Date<br>of the transaction | 2024-10-15 | ||
| f) | Place<br>of the transaction | New York Stock Exchange (XNYS) | ||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
| --- | --- | --- | --- | --- |
| a) | Name | Shobie Ramakrishnan | ||
| b) | Position/status | Chief Digital and Technology Officer | ||
| c) | Initial<br>notification/ amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | American Depositary Shares ('ADSs')<br><br><br><br><br><br>ISIN: US37733W2044 | ||
| b) | Nature<br>of the transaction | Acquisition of ADSs following the re-investment of dividends paid<br>to shareholders on 10 October 2024 | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| $39.2062 | 155.365 | |||
| d) | Aggregated<br>information | N/A (single transaction) | ||
| Aggregated<br>volume<br><br><br><br><br><br>Price | ||||
| e) | Date<br>of the transaction | 2024-10-15 | ||
| f) | Place<br>of the transaction | New York Stock Exchange (XNYS) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
| GSK plc | |
|---|---|
| (Registrant) | |
| Date: October<br>17, 2024 | |
| By:/s/ VICTORIA<br>WHYTE<br><br><br>-------------------------- | |
| Victoria Whyte | |
| Authorised<br>Signatory for and on | |
| behalf<br>of GSK plc |